|
|
|
Insider
Information: |
Eshelman Fredric N |
Relationship: |
10% Owner |
City: |
Wilmington |
State: |
NC |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
8,151,654 |
|
Indirect Shares
|
3,933,809 |
|
|
Direct
Value |
$86,486,376 |
|
|
Indirect Value
|
$13,868,647 |
|
|
Total
Shares |
12,085,463 |
|
|
Total
Value |
$100,355,023 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
7
|
3
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
7
|
3
|
|
|
|
Gain/Loss Ratio : |
-7.0
|
-3.0
|
Percentage
Gain/Loss : |
-45.7%
|
-43.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Pharmaceutical Product Developme... |
PPDI |
Executive Chairman, Di... |
2011-12-05 |
0 |
2011-12-05 |
0 |
Premium* |
|
Furiex Pharmaceuticals, Inc. |
FURX |
Director, 10% Owner |
2014-07-02 |
0 |
2014-07-02 |
0 |
Premium* |
|
Bausch Health Companies Inc |
BHC |
Director |
2017-05-05 |
38,298 |
2016-03-11 |
0 |
Premium* |
|
G1 Therapeutics Inc |
GTHX |
Director, 10% Owner |
2017-11-13 |
250,000 |
2017-11-13 |
3,439,151 |
Premium* |
|
Eyenovia Inc |
EYEN |
Director |
2020-09-11 |
1,292,787 |
2020-09-11 |
319,085 |
Premium* |
|
Liquidia Technologies Inc |
LQDA |
10% Owner |
2020-11-25 |
6,570,569 |
2020-11-25 |
175,573 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
148 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
FURX |
Furiex Pharmaceuticals, I... |
Director |
|
2014-07-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,673,522) |
0 |
0 |
- |
|
GTHX |
G1 Therapeutics Inc |
Director |
|
2017-05-22 |
4 |
B |
$15.00 |
$4,500,000 |
I/I |
300,000 |
3,439,151 |
2.25 |
- |
|
GTHX |
G1 Therapeutics Inc |
Director |
|
2017-05-22 |
4 |
A |
$0.00 |
$0 |
I/I |
3,139,151 |
3,139,151 |
0 |
- |
|
GTHX |
G1 Therapeutics Inc |
Director |
|
2017-11-13 |
4 |
B |
$19.73 |
$4,932,500 |
D/D |
250,000 |
250,000 |
3.92 |
- |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2019-12-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,159,744 |
|
- |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-03-30 |
4 |
B |
$4.76 |
$67,106 |
I/I |
14,100 |
14,100 |
1.5 |
% |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-03-31 |
4 |
B |
$4.87 |
$146,112 |
I/I |
30,000 |
44,100 |
1.5 |
% |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-04-01 |
4 |
B |
$4.89 |
$220,122 |
I/I |
45,000 |
89,100 |
1.5 |
% |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-04-02 |
4 |
B |
$4.96 |
$35,792 |
I/I |
7,223 |
96,323 |
1.5 |
% |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-04-03 |
4 |
B |
$4.85 |
$169,740 |
I/I |
35,000 |
131,323 |
1.5 |
% |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-04-06 |
4 |
B |
$5.28 |
$233,715 |
I/I |
44,250 |
175,573 |
1.5 |
% |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-07-02 |
4 |
B |
$8.00 |
$15,000,000 |
D/D |
1,875,000 |
7,034,744 |
2.45 |
% |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-11-19 |
4 |
D |
$3.35 |
$100,500 |
D/D |
(30,000) |
7,004,744 |
0 |
- |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-11-23 |
4 |
S |
$3.16 |
$421,347 |
D/D |
(133,346) |
6,871,398 |
0 |
% |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-11-24 |
4 |
S |
$3.15 |
$894,247 |
D/D |
(283,465) |
6,587,933 |
0 |
% |
|
LQDA |
Liquidia Technologies Inc |
10% Owner |
|
2020-11-25 |
4 |
S |
$3.13 |
$54,349 |
D/D |
(17,364) |
6,570,569 |
0 |
% |
|
PPDI |
Pharmaceutical Product De... |
Chief Executive Officer |
|
2004-07-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
22,000 |
4,964,263 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
Chief Executive Officer |
|
2004-07-16 |
4/A |
GD |
$0.00 |
$0 |
D/D |
22,000 |
4,964,263 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-04-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
7,000 |
4,957,263 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
4,982,263 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-05-26 |
4 |
OE |
$6.53 |
$5,706,592 |
D/D |
380,000 |
5,362,263 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-20 |
4 |
S |
$59.96 |
$9,185,899 |
D/D |
(153,000) |
5,209,263 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-21 |
4 |
S |
$59.26 |
$2,325,274 |
D/D |
(38,976) |
5,034,811 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-21 |
4 |
S |
$59.37 |
$41,500 |
D/D |
(699) |
5,060,053 |
|
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2005-07-21 |
4 |
S |
$59.40 |
$4,655,153 |
D/D |
(77,788) |
5,074,486 |
|
- |
|
148 Records found
|
|
Page 3 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|